BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

883 related articles for article (PubMed ID: 28377178)

  • 1. Targeting KDM1A attenuates Wnt/β-catenin signaling pathway to eliminate sorafenib-resistant stem-like cells in hepatocellular carcinoma.
    Huang M; Chen C; Geng J; Han D; Wang T; Xie T; Wang L; Wang Y; Wang C; Lei Z; Chu X
    Cancer Lett; 2017 Jul; 398():12-21. PubMed ID: 28377178
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the Wnt/β-catenin signaling pathway improves the anti-tumor effects of sorafenib against hepatocellular carcinoma.
    Lin HH; Feng WC; Lu LC; Shao YY; Hsu CH; Cheng AL
    Cancer Lett; 2016 Oct; 381(1):58-66. PubMed ID: 27431312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
    He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
    Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
    [TBL] [Abstract][Full Text] [Related]  

  • 5. WM130 preferentially inhibits hepatic cancer stem-like cells by suppressing AKT/GSK3β/β-catenin signaling pathway.
    Ni CX; Qi Y; Zhang J; Liu Y; Xu WH; Xu J; Hu HG; Wu QY; Wang Y; Zhang JP
    Oncotarget; 2016 Nov; 7(48):79544-79556. PubMed ID: 27783993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bruceine D inhibits hepatocellular carcinoma growth by targeting β-catenin/jagged1 pathways.
    Cheng Z; Yuan X; Qu Y; Li X; Wu G; Li C; Zu X; Yang N; Ke X; Zhou J; Xie N; Xu X; Liu S; Shen Y; Li H; Zhang W
    Cancer Lett; 2017 Sep; 403():195-205. PubMed ID: 28645563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhamnetin induces sensitization of hepatocellular carcinoma cells to a small molecular kinase inhibitor or chemotherapeutic agents.
    Jia H; Yang Q; Wang T; Cao Y; Jiang QY; Ma HD; Sun HW; Hou MX; Yang YP; Feng F
    Biochim Biophys Acta; 2016 Jul; 1860(7):1417-30. PubMed ID: 27091611
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An isocorydine derivative (d-ICD) inhibits drug resistance by downregulating IGF2BP3 expression in hepatocellular carcinoma.
    Li M; Zhang L; Ge C; Chen L; Fang T; Li H; Tian H; Liu J; Chen T; Jiang G; Xie H; Cui Y; Yao M; Li J
    Oncotarget; 2015 Sep; 6(28):25149-60. PubMed ID: 26327240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
    Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
    PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PPARδ Reprograms Glutamine Metabolism in Sorafenib-Resistant HCC.
    Kim MJ; Choi YK; Park SY; Jang SY; Lee JY; Ham HJ; Kim BG; Jeon HJ; Kim JH; Kim JG; Lee IK; Park KG
    Mol Cancer Res; 2017 Sep; 15(9):1230-1242. PubMed ID: 28584024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
    Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
    Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phosphorylated ERK is a potential prognostic biomarker for Sorafenib response in hepatocellular carcinoma.
    Liang Y; Chen J; Yu Q; Ji T; Zhang B; Xu J; Dai Y; Xie Y; Lin H; Liang X; Cai X
    Cancer Med; 2017 Dec; 6(12):2787-2795. PubMed ID: 29030911
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MK2206 overcomes the resistance of human liver cancer stem cells to sorafenib by inhibition of pAkt and upregulation of pERK.
    Zhai B; Zhang X; Sun B; Cao L; Zhao L; Li J; Ge N; Chen L; Qian H; Yin Z
    Tumour Biol; 2016 Jun; 37(6):8047-55. PubMed ID: 26711788
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An artificial lncRNA targeting multiple miRNAs overcomes sorafenib resistance in hepatocellular carcinoma cells.
    Tang S; Tan G; Jiang X; Han P; Zhai B; Dong X; Qiao H; Jiang H; Sun X
    Oncotarget; 2016 Nov; 7(45):73257-73269. PubMed ID: 27689326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma.
    Chen J; Jin R; Zhao J; Liu J; Ying H; Yan H; Zhou S; Liang Y; Huang D; Liang X; Yu H; Lin H; Cai X
    Cancer Lett; 2015 Oct; 367(1):1-11. PubMed ID: 26170167
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of MMP-2 Expression Enhances the Antitumor Effect of Sorafenib in Hepatocellular Carcinoma by Suppressing the PI3K/AKT/mTOR Pathway.
    Tan W; Zhu S; Cao J; Zhang L; Li W; Liu K; Zhong J; Shang C; Chen Y
    Oncol Res; 2017 Nov; 25(9):1543-1553. PubMed ID: 28276313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sorafenib pretreatment enhances radiotherapy through targeting MEK/ERK/NF-κB pathway in human hepatocellular carcinoma-bearing mouse model.
    Chen JC; Chuang HY; Hsu FT; Chen YC; Chien YC; Hwang JJ
    Oncotarget; 2016 Dec; 7(51):85450-85463. PubMed ID: 27863427
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long non-coding RNA TUC338 is functionally involved in sorafenib-sensitized hepatocarcinoma cells by targeting RASAL1.
    Jin W; Chen L; Cai X; Zhang Y; Zhang J; Ma D; Cai X; Fu T; Yu Z; Yu F; Chen G
    Oncol Rep; 2017 Jan; 37(1):273-280. PubMed ID: 27878301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.